Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02296125 · MORE INFO

Limitations, agreements, and source contact

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
There were 19 Chinese participants who were included in both the global and China cohort which gives a total of 692 participants instead of a total of 673 participants.
point Of Contact
email
ClinicalTrialTransparency@astrazeneca.com
organization
AstraZeneca AB
phone
+46 766 346712
title
Global Clinical Leader
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
There were 19 Chinese participants who were included in both the global and China cohort which gives a total of 692 participants instead of a total of 673 participants.
point Of Contact
email
ClinicalTrialTransparency@astrazeneca.com
organization
AstraZeneca AB
phone
+46 766 346712
title
Global Clinical Leader

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice